Search Results for "michigan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for michigan. Results 161 to 170 of 308 total matches.
Recombinant Human Antithrombin (ATryn)
The Medical Letter on Drugs and Therapeutics • Oct 19, 2009 (Issue 1323)
., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein College of Medicine
David N ...
The FDA has approved the use of recombinant human antithrombin (rhAT; ATryn - Lundbeck) in patients with inherited antithrombin (AT) deficiency to prevent thrombosis during or after surgery or childbirth. The protein is produced in the milk of transgenic goats carrying a copy of the human cDNA for AT. This is the first US drug approval for a protein produced by a transgenic animal. ATryn has been used in Europe since 2006.
Aliskiren/Valsartan (Valturna) for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009 (Issue 1326)
., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein College of Medicine
David N ...
The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment of hypertension in patients already taking both drugs or not adequately controlled on monotherapy, and as initial therapy in those likely to need multiple drugs to control their blood pressure.
Tolvaptan (Samsca) for Hyponatremia
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009 (Issue 1326)
College of Physicians and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School ...
The FDA has approved the marketing of tolvaptan (Samsca - Otsuka), an oral vasopressin receptor antagonist, for treatment of hypervolemic or euvolemic hyponatremia due to congestive heart failure (CHF), cirrhosis or the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A similar drug, conivaptan (Vaprisol) is already available for intravenous (IV) treatment of euvolemic hyponatremia in hospitalized patients. Tolvaptan was approved by the FDA for both inpatient and outpatient use, but it should be started in a hospital.
Screening Mammography for Women 40-49 Years Old
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009 (Issue 1327)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein ...
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening mammography for women 40-49 years old conflicts with recommendations made by other organizations such as the American Cancer Society and earlier recommendations made by the USPSTF in 2002.
Click here to view the free full article.
Click here to view the free full article.
Rapid-Acting Insulin Analogues
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009 (Issue 1327)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein ...
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous injection, insulin pump or intravenous administration. All three cost more than regular insulin.
A Third Amlodipine/ARB Combination (Twynsta) for Hypertension
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010 (Issue 1329)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein ...
The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of hypertension.
In Brief: Stopping Long-Acting Beta-2 Agonists
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
College of Physicians and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School ...
A little more than a year ago, The Medical Letter reported the results of an FDA meta-analysis which found that use of a long-acting beta-2 agonist (LABA) such as salmeterol (Severent) or formoterol (Foradil) in patients with asthma was associated with an increased risk of a composite endpoint of asthma-related death, intubation or hospitalization; the highest risk was in children 4-11 years old.There was no significant increase in risk when a long-acting beta-2 agonist was used with an inhaled corticosteroid.The Medical Letter recommended that long-acting beta-2 agonists should not be used as...
L-Methylfolate (Deplin) for Depression and Schizophrenia
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
David N ...
L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels. It is available only by prescription.
Which TNF Inhibitor for Rheumatoid Arthritis?
The Medical Letter on Drugs and Therapeutics • May 17, 2010 (Issue 1338)
University College of Physicians and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan ...
The FDA has approved five tumor necrosis factor (TNF) inhibitors for treatment of moderately to
severely active rheumatoid arthritis (RA). TNF-α is a pro-inflammatory cytokine involved in the pathogenesis of many systemic inflammatory disorders.
A Plasma-derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
The Medical Letter on Drugs and Therapeutics • Jun 14, 2010 (Issue 1340)
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert ...
The FDA has approved a new plasma-derived von Willebrand factor/Factor VIII concentrate (Wilate –
Octapharma) for treatment of spontaneous and trauma-induced bleeding episodes in patients with von
Willebrand disease.